Compare Arqit Quantum Inc (ARQQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Arqit Quantum Inc trades at $17.71 (market cap $332.04M), while State Street SPDR S&P Biotech ETF trades at $154.27. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | XBI | |
|---|---|---|
Market Cap | $332.04M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $58.27 | $164.28 |
52-Week Low | $11.78 | $85.16 |
Enterprise Value | $305.35M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
XBI, the SPDR S&P Biotech ETF, trades at $159.03, down 3.2% over the past day amid a broader market pullback, though it remains in a strong uptrend with a 17% gain over the past month. Technical indicators are bullish overall, but RSI levels suggest overbought conditions. The ETF's equal-weight exposure to biotech stocks drives high volatility and significant upside during sector rallies, with recent news highlighting booming biotech M&A and AI-driven drug discovery as key catalysts.
The outlook for XBI is positive given sector momentum and favorable deal activity, though its high beta and reliance on small- to mid-cap biotech stocks pose risks during market downturns. Analyst sentiment is neutral with a single hold rating, reflecting caution amid elevated valuations. Investors should weigh the sector's growth potential against inherent volatility and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
